Helus Pharma Partners with TARA Mind to Accelerate HLP003 Phase 3 Recruitment for Veteran Mental Health
HELP sits 21% above its 52-week low of $4.29.
Summary
Helus Pharma (Cybin Inc.) announced a partnership with TARA Mind and VETS to boost recruitment for its HLP003 Phase 3 clinical trial for Major Depressive Disorder, particularly within the veteran community, aligning with a recent Executive Order.
Key Events · Product Development and Regulatory · HELP
-
Strategic Partnership for Clinical Trial Recruitment
Helus Pharma (Cybin Inc.) has partnered with TARA Mind and Veterans Exploring Treatment Solutions (VETS) to support recruitment for its PARADIGM HLP003 Phase 3 program for Major Depressive Disorder.
-
Advancing Breakthrough Therapy Designated Drug
The collaboration aims to accelerate the Phase 3 trial for HLP003, which has received Breakthrough Therapy Designation from the U.S. FDA, a critical step towards potential market approval.
-
Alignment with Executive Order on Veteran Mental Health
This initiative directly supports President Trump's April 18, 2026 Executive Order, 'Accelerating Medical Treatments for Serious Mental Illness,' by expanding research participation and access for veterans.
Analysis · HELP · Life Sciences
This collaboration is a significant positive development for Helus Pharma, a clinical-stage pharmaceutical company. Partnering with TARA Mind and VETS directly addresses a critical hurdle for their lead drug candidate, HLP003, by facilitating recruitment for its Phase 3 clinical trial. HLP003 already holds FDA Breakthrough Therapy Designation for Major Depressive Disorder, making efficient trial progression vital. The partnership also strategically aligns with a recent White House Executive Order focused on advancing mental health treatments for veterans, potentially broadening the drug's reach and impact within a high-need population. This move de-risks the clinical development pathway and enhances the company's profile in a key therapeutic area.
At the time of this filing, HELP was trading at $5.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.29 to $9.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.